This partly explains why hypoglycaemia is much less problem in those with the overweight insulin‐resistant phenotype, but also why it has been difficult to show improved control with modern basal insulins of more appropriate diurnal plasma profiles compared to historical intermediate‐acting insulins in treat‐to‐target clinical trials.25, 26. The gene discussed is INS; the disease is Hypoglycemia.